WEX Expands GLP-1 HRA Solution With Virtual Access Options, Member Support and Outcomes Management
Business Wire•19/11/2026•09:00 ET
0
Key Highlights
- ➤WEX expands GLP-1 HRA with Patiently and Signos integrations
- ➤Patiently adds customizable GLP-1 treatment plans and ongoing clinical support
- ➤Signos adds telehealth screening, metabolic monitoring, coaching, and outcomes reporting
- ➤GLP-1 medications represent approximately 20% of enterprise pharmacy spend
- ➤List prices average $900 to $1,500 monthly; about 35% discontinued early in 2025
Expert Statements
Robert Deshaies, Chief Operating Officer, Benefits at WEX
“Employees shouldn’t have to drain their savings or navigate a maze of branded portals just to access transformative care like GLP-1s”
Robert Deshaies, Chief Operating Officer, Benefits at WEX
“At the same time, handing someone a high-cost prescription without guidance makes long-term success far harder to achieve and sustain.”
Robert Deshaies, Chief Operating Officer, Benefits at WEX
“By pairing predictable HRA funding with telehealth support and real-time metabolic coaching, WEX and our providers are removing anxiety and friction for workers, and instead providing them with the confidence and reliable access they need to help build lasting health – all while giving employers sustainable costs.”
WEX Expands GLP-1 HRA Solution With Virtual Access Options, Member Support and Outcomes Management
New offering with Patiently™ and Signos combines employer-controlled HRA funding, clinically guided GLP-1 access, and AI-powered lifestyle coaching – all in a single, flexible benefits solution
Get started
Create a free account to read the full story.
